Individual tumor suppression strategy using cancer antigen peptides in oral cancers

在Kurdom大学免疫学系鉴定的31种癌抗原肽中，我们研究了p56^<lck>和SART-3癌抗原肽成为口腔鳞状细胞癌患者特异性癌症疫苗治疗靶分子的可能性。受试者是口腔鳞状细胞癌的原发病例，在库尔斯克大学医学院牙科和口腔医学中心接受治疗。用<lck>抗兔单克隆抗体免疫组化法检测p56抗原的表达，阳性率为48%（13/27）。此外，使用RT-PCR方法，证实了p56 α<lck>和SART-3分子在口腔鳞状细胞癌细胞系（HSC-2、HSC-3、HSC-4、Ca 9 -22、KUMA-1、SAS）和口腔癌切除组织中的表达。另一方面，使用蛋白质印迹法，评价SART-3抗原在细胞核和胞质组分中的表达，并且在每个细胞系中表达率为100%。在口腔癌切除组织中，在核组分中的表达率为19/31（61%），在胞浆组分中的表达率为12/31（39%）。此外，使用ELISA方法测量IFN-γ产生的量，我们评估了p56 β和SART-3肽对HLA-24限制性CTL的诱导<lck>，并且证实了来自口腔鳞状细胞癌患者外周血的CTL的肽特异性诱导。考虑到这些结果以及大约60%的日本人具有HLA-A24，存在p56 α<lck>和SART-3分子可用作定制肽疫苗疗法中的靶分子的可能性。

Among 31 types of cancer antigen peptide, which were identified by the Department of Immunology, Kurume University, we investigated the possibility of p56^<lck> and SART-3 cancer antigen peptides becoming target molecules of specific cancer vaccine therapy for patients with oral squamous cell carcinoma. The subjects were primary cases of oral squamous cell carcinoma, which were treated in the Dental and Oral Medical Center, Kurume University School of Medicine. We immunohistochemically evaluated the expression of p56^<lck> antigen, using anti-rabbit monoclonal antibodies, and the positive rate was 13/27 (48%). Furthermore, using the RT-PCR method, the expression of p56^<lck> and SART-3 molecules in the cell lines of oral squamous cell carcinoma (HSC-2, HSC-3, HSC-4, Ca9-22, KUMA-1, SAS) and oral cancer resection tissue was confirmed. On the other hand, using the Western blotting method, the expression of SART-3 antigen in the nuclear and cytosolic fractions was evaluated, and the expression rate was 100% in each cell line. In the oral cancer resection tissue, the expression rate was 19/31 (61%)in the nuclear fraction and 12/31 (39%)in the cytosolic fraction. Furthermore, measuring the amount of IFN-γ production using the ELISA method, we evaluated the HLA-24-restricted induction of CTL by p56^<lck> and SART-3 peptides, and peptide-specific induction of CTL was confirmed from the peripheral blood in patients with oral squamous cell carcinoma. Considering these results and that approximately 60% of Japanese people have HLA-A24, there is a possibility that p56^<lck> and SART-3 molecules can be used as target molecules in tailor-made peptide vaccine therapy.